Proactive Investors - Run By Investors For Investors

Rhinomed shares jump 75% on enhanced breathing device enthusiasm

Rhinomed shares jump 75% on enhanced breathing device enthusiasm

Rhinomed (ASX:RNO) shares have traded 75% higher today, hitting an intraday high of $0.043 after closing yesterday at $0.024.

Shares in the company last traded at $0.038.

Rhinomed manufactures and sells its Turbine enhanced breathing device which purportedly increases the amount of air and oxygen that can pass through the nasal passages and into the lungs.

It is being targeted for use in athletes and particularly cyclists.

In early June, the company reported that it had now attracted 13,152 new subscribers to its subscriber database.

The broader drive through both online and offline media, including campaigns with and is exposing the Turbine brand to ‘qualified’ cyclists’ and athletes.

All those who have joined the Turbine subscriber base have expressed high-level interest in cycling and are now being introduced to the benefits of the Turbine.

The recent Ridewiser Trial results showed some Turbine users could generate an additional 6.5% in power, and Rhinomed has been working with Tour de France green jersey winner Baden Cooke in Europe to introduce the Turbine to the world’s leading cyclists and teams.

The company has also enlisted Giant Bike stores and Bicycles Inc. as Australian retail outlets.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

View full RNO profile View Profile

Rhinomed Ltd Timeline

September 15 2015

Related Articles

February 01 2019
The cancer detection device is on track to finish a key clinical study in the first quarter of 2019, but in the meantime, it has shown promise in detecting abnormalities in unborn children
A woman with severe depression
April 25 2019
The New York clinical-stage biopharmaceutical company has several drugs in the pipeline capable of generating hefty revenue
February 20 2019
Earlier this month, Tissue Regenix reported full-year results showing revenues more than doubled last year to £11.6mln, up from £5.2mln a year earlier
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use